Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton

has a problem with its eye-care unit : It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year financials. But the company's sales and earnings didn't fall short just because of .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS